HIGHLIGHTS
- who: Alexandra Tsankof from the Beirut Arab University, Lebanon Vanvitelli, Italy have published the paper: Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?, in the Journal: (JOURNAL)
- what: Several agents are currently approved for the management of obesity.
- how: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- future: More studies are needed to evaluate their effects on liver-related and cardiovascular outcomes in patients with NAFLD particularly . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.